Russian Heart Failure Journal 2010year Angiotensin II AT1 receptor antagonist valsartan in patients with chronic heart failure

To access this material please log in or register

Register Authorize

Angiotensin II AT1 receptor antagonist valsartan in patients with chronic heart failure

Maximov M. L., Derbentseva E. A., Dralova O. V., Starodubtsev A. K., Ostroumova O. D.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: ARB, valsartan, CHF

DOI: 10.18087/rhfj.2010.5.1429

Angiotensin receptor blockers (ARB) valsartan is one of the most studied and most commonly prescribed ARB. It combines high efficacy and good tolerance, lack of significant drug interactions and simple to use. The article presents own clinical experience in evaluation of therapeutic efficacy of Valsakor (generic valsartan) in patients with CHF. Valsakor is bioequivalent to original valsartan and has demonstrated its efficacy and safety.
  1. Gasparo M, Catt KJ, Inagami T et al. International Union of Pharma­cology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52 (3):415–472.
  2. Goodfriend ТL Angiotensins: actions and receptors. In Oparil S, Weber MA (eds). Hypertension: A Companion to Brenner and Rector’s The Kidney. Edition Philadelphia, Pennsylvania, US: W. B. Saunders Co; 2000:11–13.
  3. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;334 (25):1649–1654.
  4. Клиническая фармакология: учебник для мед. вузов / под ред. В. Г. Кукеса. – Изд. 4‑е, перераб. и доп. – М.: ГЭОТАР-Медиа, 2008. – 1056 с.
  5. Brugts JJ, den Uil CA, Danser AH, Boersma E. The renin-angiotensin-aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology. 2009;112 (4):303–312.
  6. Weber MA. Angiotensin II receptor blockers. In Oparil S, Weber MA (eds). Hypertension: A Companion to Brenner and Rector’s The Kidney. Edition Philadelphia, Pennsylvania, US: W. B. Saunders Co; 2000:377–378.
  7. Кобалава Ж. Д., Гудков К. М. Эволюция представлений о стресс – индуцированной артериальной гипертонии и применение антагонистов рецепторов ангиотензина II. Кардиоваскулярная терапия и профилактика. 2002;1 (1):4–15.
  8. Weir MR. Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. Curr Hypertens Rep. 2002;4 (5):333–335.
  9. Waldmeier F, Flesch G, Müller P Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose et al. Xenobiotica. 1997;27 (1):59–71.
  10. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25 (6):1105–1187.
  11. Моисеев С. В. Валсартан: от реалий клинической практики к новым возможностям. Клиническая фармакология и фармакотерапия. 2009;18 (3):72–77.
  12. Lacourcière Y, Poirier L, Hebert D et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8‑week, randomized, double-blind, parallel-group trial. Clin Ther. 2005;27 (7):1013–1021.
  13. Malacco E, Varì N, Capuano V et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther. 2003;25 (11):2765–80.
  14. Destro M, Scabrosetti R, Vanasia A, Mugellini A. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24‑hour ambulatory blood pressure monitoring. Adv Ther. 2005;22 (1):32–43.
  15. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Доступно на: /upload / ossn_pdf / Recomend /Guidelines%20SSHF%20rev.3.01 %202010.pdf
  16. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362 (9386):772–776.
  17. McMurray JJV, Ostergren J, Swedberg K et al; for the CHARM investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362 (9386):767–771.
  18. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left – ventricular ejection fraction: the CHARM Preserved Trial. Lancet. 2003;362 (9386):777–781.
  19. Pitt B, Poole – Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355 (9215):1582–1587.
  20. Konstam MA, Neaton J D, Dickstein K et al. Eff ects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374 (9704):1840–1848.
  21. Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369 (9571):1431–1439.
  22. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358 (15):1547–1559.
  23. Yusuf S, Teo K, Anderson C et al. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372 (9644):1174–1183.
  24. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359 (23):2456–2467.
  25. Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens. 2004;22 (4):837–846.
  26. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345 (23):1667–1675.
  27. Maggioni AР, Anand I, Gottlieb SO et al. Effects of Valsartan on Morbidity and Mortality in Patients With Heart Failure Not Receiving Angiotensin – Converting Enzyme Inhibitors J Am Coll Cardiol. 2002;40 (8):1414–1421.
  28. Cohn JN, Anand IS, Latini R et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation. 2003;108 (11):1306–1309.
  29. Wong M, Staszewsky L, Latini R et al. Valsartan benefits left ventricular structure and function in heart Failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40 (5):970–975.
  30. Schmieder R, Hua T. Reduced Incidence of New Onset Atrial Fibrillation with Angiotensin II Receptor Blockade: The VALUE-Trial. J Hypertens. 2006;24 (Suppl):S3.
  31. Julius S, Kjeldsen SE, Brunner H et al. VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16 (7):544–548.
  32. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363 (9426):2022–2031.
  33. Julius S, Weber MA, Kjeldsen SE et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006;48 (3):385–391.
  34. Maggioni AP, Latini R, Carson PE et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149 (3):548–557.
  35. Mutlu H, Ozhan H, Okçün B et al. The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy. Blood Press. 2002;11 (1):53–55.
  36. Thürmann PA, Kenedi P, Schmidt A et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 1998;98 (19):2037–2042.
  37. Клинико-фармакологические аспекты взаимодействия лекарственных средств. Под ред. В. Г. Кукеса – М: Издательский дом «Русский врач», 2007. – 19–28, 94–95.
  38. Viberti G, Wheeldon NM. For the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106 (6):672–678.
  39. Сидоренко Б. А., Преображенский Д. В. Блокаторы АТ1‑ангио­тензи­новых рецепторов. (монография). – М.:Морион, 2001. – 200 с.
  40. Benz J, Oshrain C, Henry D et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997;37 (2):101–107.
  41. Perico N, Spormann D, Peruzzi E et al. Efficacy and tolerability of valsartan compared with lisinopril in patients with hypertension and renal insufficiency. Clin Drug Invest. 1997;14:252–259.
  42. Holwerda NJ, Fogari R, Angeli P et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996;14 (9):1147–1151.
  43. Hollenberg NK, Parving HH, Viberti G et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25 (9):1921–1926.
  44. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20 (4): 671–681.
  45. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366 (9502):2026–2033.
  46. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148 (1):30–48.
Maximov M. L., Derbentseva E. A., Dralova O. V. et al. Angiotensin II AT1 receptor antagonist valsartan in patients with chronic heart failure. Russian Heart Failure Journal. 2010;11(5):301-305.

To access this material please log in or register

Register Authorize
Ru En